In most gliomas, ATRX deletion in combination with IDH mutation leads to immunosuppression, whereas IDH-mutant, ATRX-mutant astrocytomas exhibit greater immune cell infiltration than IDH-mutant, ATRX wild-type oligodendrogliomas (Venteicher et al., 2017). The gene discussed is ATRX; the disease is central nervous system cancer.